37,461 Shares in Theravance Biopharma, Inc. (NASDAQ:TBPH) Bought by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio purchased a new stake in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 37,461 shares of the biopharmaceutical company's stock, valued at approximately $353,000. Public Employees Retirement System of Ohio owned 0.08% of Theravance Biopharma at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. SG Americas Securities LLC boosted its position in shares of Theravance Biopharma by 21.1% during the 4th quarter. SG Americas Securities LLC now owns 19,202 shares of the biopharmaceutical company's stock valued at $181,000 after acquiring an additional 3,349 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Theravance Biopharma by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 293,936 shares of the biopharmaceutical company's stock worth $2,766,000 after purchasing an additional 2,060 shares during the period. Teacher Retirement System of Texas bought a new position in Theravance Biopharma during the fourth quarter worth about $103,000. Magnetar Financial LLC boosted its holdings in Theravance Biopharma by 125.8% during the fourth quarter. Magnetar Financial LLC now owns 27,511 shares of the biopharmaceutical company's stock valued at $259,000 after purchasing an additional 15,328 shares in the last quarter. Finally, American Century Companies Inc. boosted its holdings in Theravance Biopharma by 11.9% during the fourth quarter. American Century Companies Inc. now owns 77,931 shares of the biopharmaceutical company's stock valued at $733,000 after purchasing an additional 8,289 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company's stock.

Insider Activity at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 24,000 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $11.00, for a total value of $264,000.00. Following the completion of the transaction, the senior vice president now owns 336,918 shares in the company, valued at $3,706,098. The trade was a 6.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 6.90% of the stock is currently owned by company insiders.

Theravance Biopharma Stock Up 4.5%

NASDAQ:TBPH traded up $0.48 on Friday, reaching $11.25. The stock had a trading volume of 295,003 shares, compared to its average volume of 275,237. The company has a market capitalization of $562.51 million, a P/E ratio of -11.14 and a beta of -0.10. Theravance Biopharma, Inc. has a 1-year low of $7.44 and a 1-year high of $11.82. The stock has a fifty day moving average price of $9.31 and a 200-day moving average price of $9.39.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.16). The firm had revenue of $15.39 million during the quarter, compared to the consensus estimate of $28.08 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. Sell-side analysts predict that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on TBPH. HC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of Theravance Biopharma in a report on Tuesday, February 25th. Wall Street Zen upgraded Theravance Biopharma from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $11.33.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.